Literature DB >> 8230553

Characterization and localization of prostatic alpha 1 adrenoceptors using radioligand receptor binding on slide-mounted tissue section.

S Kobayashi1, R Tang, E Shapiro, H Lepor.   

Abstract

Alpha 1 adrenoceptor binding sites have been characterized in prostatic tissue homogenates using radioligand receptor binding studies. The objective of the present study was to characterize and localize prostatic alpha 1 adrenoceptor binding sites using slide-mounted tissue sections and the ligand 3H-prazosin. The present study demonstrated that preincubation is not required; the optimal incubation interval is 40 minutes; and a 1-minute wash (once or twice) maximizes the proportion of specific 3H-prazosin binding. Saturation studies were performed at 8 different concentrations of 3H-prazosin ranging between 0.0625 nM. to 8.0 nM. The binding of 3H-prazosin was consistently saturable and of high affinity. The mean Kd and Bmax determined from 6 saturation studies was 4.16 x 10(-10) M. and 1.30 fmol./mg. wet weight, respectively. The pharmacology of these 3H-prazosin binding sites was characterized using competitive displacement experiments. The mean IC50 corrected for prazosin, phentolamine and yohimbine was 7.8 x 10(-10) M., 6.0 x 10(-9) M. and 2.1 x 10(-6) M. The rank order of the IC50 corrected values indicates that alpha 1 binding sites were measured under the assay conditions. In the present study, the mean values for Kd, Bmax and IC50 corrected are similar to values previously reported using prostatic tissue homogenates. Prostatic tissue sections were apposed to x-ray film after being incubated with 3 nM. 3H-prazosin (total prazosin binding) and 3 nM. 3H-prazosin + 8 microM. prazosin (nonspecific prazosin binding). The autoradiograms were analyzed using a computerized analyzing system. The specific radioactive densities of 3H-prazosin in the stroma and glandular epithelium were 1099 +/- 48 pCi/mg. and 163 +/- 42 pCi/mg. The present study validates the technique of assaying alpha 1 adrenoceptor binding sites on slide-mounted prostatic tissue sections and provides further evidence that alpha 1 adrenoceptor binding sites are localized primarily to the stromal elements of the prostate.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8230553     DOI: 10.1016/s0022-5347(17)35954-2

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  13 in total

1.  Pathophysiology of benign prostatic hyperplasia: insights from medical therapy for the disease.

Authors:  Herbert Lepor
Journal:  Rev Urol       Date:  2009

Review 2.  Combination pharmacological therapies for the management of benign prostatic hyperplasia.

Authors:  Seth A Cohen; J Kellogg Parsons
Journal:  Drugs Aging       Date:  2012-04-01       Impact factor: 3.923

3.  The evolution of alpha-blockers for the treatment of benign prostatic hyperplasia.

Authors:  Herbert Lepor
Journal:  Rev Urol       Date:  2006

Review 4.  Medical and Surgical Treatment Modalities for Lower Urinary Tract Symptoms in the Male Patient Secondary to Benign Prostatic Hyperplasia: A Review.

Authors:  Matthew Ryan Macey; Mathew C Raynor
Journal:  Semin Intervent Radiol       Date:  2016-09       Impact factor: 1.513

5.  Alpha-blockers and intraoperative floppy iris syndrome: ophthalmic adverse events following cataract surgery.

Authors:  Zuhair K Al-Hussaini; Kevin T McVary
Journal:  Curr Urol Rep       Date:  2010-07       Impact factor: 3.092

6.  Alpha blockers for the treatment of benign prostatic hyperplasia.

Authors:  Herbert Lepor
Journal:  Rev Urol       Date:  2007

7.  Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies.

Authors:  B A Kenny; A M Miller; I J Williamson; J O'Connell; D H Chalmers; A M Naylor
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

Review 8.  Treatment of benign prostatic hyperplasia in hypertensive men.

Authors:  William B White; Timothy Moon
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-04       Impact factor: 3.738

Review 9.  Role of α- and β-adrenergic signaling in phenotypic targeting: significance in benign and malignant urologic disease.

Authors:  M Archer; N Dogra; Z Dovey; T Ganta; H-S Jang; J A Khusid; A Lantz; M Mihalopoulos; J A Stockert; A Zahalka; L Björnebo; S Gaglani; M R Noh; S A Kaplan; R Mehrazin; K K Badani; P Wiklund; K Tsao; D J Lundon; N Mohamed; F Lucien; B Padanilam; M Gupta; A K Tewari; N Kyprianou
Journal:  Cell Commun Signal       Date:  2021-07-20       Impact factor: 5.712

10.  Effect of Transurethral Resection of the Prostate on Storage Symptoms in Patients with Benign Prostatic Hyperplasia of Less than 30 ml.

Authors:  Yu Jin Kang; Ki Ho Kim; Youngjin Seo; Kyung Seop Lee
Journal:  World J Mens Health       Date:  2013-04-23       Impact factor: 5.400

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.